Drug Trial Radar · NCT03855917
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Feb 11, 2020
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Kirby InstituteGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Feb 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
Conditions
- Hepatitis C
Interventions
Sofosbuvir 400mg [Sovaldi]Drug
Four weeks.
Glecaprevir/pibrentasvir (300mg/120mg)Drug
Four weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SVR12Time frame: 16 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
St Vincent's Hospital
Darlinghurst, New South Wales, Australia · Recruiting
Blacktown Mt Druitt Hospital
Sydney, New South Wales, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.